Revolution Medicines — Third Quarter 2026 Earnings Summary

Revolution Medicines received U.S. FDA approval and launched RASONQUE (daraxonrasib) for metastatic pancreatic cancer, generating $197.6 million in net product revenue during the third quarter of 2026. The company also secured a positive CHMP opinion recommending marketing authorization for the drug in the European Union. Financial results for the quarter ended September 30, 2026, reported a net loss of $407.5 million, driven by increased research and development and selling expenses associated with the commercial launch. Additionally, the company triggered a $250 million debt tranche from Royalty Pharma following the U.S. approval and continues to advance multiple Phase 3 clinical trials across pancreatic cancer, lung cancer, and colorectal cancer.